Integra LifeSciences (NASDAQ:IART) Stock Price Down 4.4% – Should You Sell?

Integra LifeSciences Holdings Co. (NASDAQ:IART) shares traded down 4.4% on Monday . The stock traded as low as $21.61 and last traded at $22.15. 303,470 shares changed hands during trading, a decline of 11% from the average session volume of 341,422 shares. The stock had previously closed at $23.17.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the stock. Morgan Stanley assumed coverage on shares of Integra LifeSciences in a research report on Monday, December 2nd. They issued an “underweight” rating and a $20.00 price objective for the company. Bank of America cut their price target on shares of Integra LifeSciences from $26.00 to $18.00 and set an “underperform” rating for the company in a report on Monday, October 7th. Truist Financial decreased their price target on shares of Integra LifeSciences from $26.00 to $21.00 and set a “hold” rating on the stock in a report on Monday, October 14th. BTIG Research raised Integra LifeSciences from a “sell” rating to a “neutral” rating in a research note on Monday, October 7th. Finally, Citigroup upped their target price on Integra LifeSciences from $16.00 to $22.00 and gave the stock a “sell” rating in a research note on Tuesday, November 5th. Three investment analysts have rated the stock with a sell rating, five have issued a hold rating and one has issued a buy rating to the company’s stock. According to data from MarketBeat.com, Integra LifeSciences presently has an average rating of “Hold” and an average price target of $23.00.

Integra LifeSciences Stock Down 6.3 %

The stock has a 50-day simple moving average of $23.17 and a two-hundred day simple moving average of $22.88. The company has a quick ratio of 0.73, a current ratio of 1.20 and a debt-to-equity ratio of 0.79. The firm has a market cap of $1.67 billion, a PE ratio of -241.08, a P/E/G ratio of 0.82 and a beta of 1.16.

Integra LifeSciences (NASDAQ:IART) last released its earnings results on Monday, November 4th. The life sciences company reported $0.41 earnings per share for the quarter, topping analysts’ consensus estimates of $0.39 by $0.02. Integra LifeSciences had a positive return on equity of 12.35% and a negative net margin of 0.42%. The company had revenue of $380.80 million during the quarter, compared to the consensus estimate of $375.81 million. During the same quarter in the previous year, the company posted $0.76 EPS. Integra LifeSciences’s quarterly revenue was down .4% compared to the same quarter last year. Analysts expect that Integra LifeSciences Holdings Co. will post 2.45 earnings per share for the current year.

Insider Activity

In related news, EVP Michael J. Mcbreen sold 1,700 shares of the firm’s stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $24.16, for a total transaction of $41,072.00. Following the transaction, the executive vice president now directly owns 56,182 shares in the company, valued at $1,357,357.12. This trade represents a 2.94 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 3.10% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Sachem Head Capital Management LP bought a new stake in Integra LifeSciences during the 3rd quarter valued at $44,153,000. Dimensional Fund Advisors LP grew its stake in shares of Integra LifeSciences by 0.7% in the second quarter. Dimensional Fund Advisors LP now owns 1,785,009 shares of the life sciences company’s stock worth $52,014,000 after purchasing an additional 12,766 shares during the last quarter. Charles Schwab Investment Management Inc. increased its holdings in Integra LifeSciences by 15.3% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 944,282 shares of the life sciences company’s stock valued at $17,158,000 after purchasing an additional 125,620 shares during the period. D. E. Shaw & Co. Inc. raised its position in Integra LifeSciences by 64.6% during the 2nd quarter. D. E. Shaw & Co. Inc. now owns 855,352 shares of the life sciences company’s stock valued at $24,925,000 after purchasing an additional 335,557 shares during the last quarter. Finally, Glenmede Trust Co. NA lifted its holdings in Integra LifeSciences by 125.9% in the 3rd quarter. Glenmede Trust Co. NA now owns 727,781 shares of the life sciences company’s stock worth $13,224,000 after buying an additional 405,624 shares during the period. Institutional investors own 84.78% of the company’s stock.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.